Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleCARDIOVASCULAR

Characterization of Contractile P2 Receptors in Human Coronary Arteries by Use of the Stable Pyrimidines Uridine 5′-O-Thiodiphosphate and Uridine 5′-O-3-Thiotriphosphate

Malin Malmsjö, Mingyan Hou, T. Kendall Harden, William Pendergast, Emil Pantev, Lars Edvinsson and David Erlinge
Journal of Pharmacology and Experimental Therapeutics June 2000, 293 (3) 755-760;
Malin Malmsjö
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mingyan Hou
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
T. Kendall Harden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William Pendergast
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emil Pantev
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lars Edvinsson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Erlinge
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The present study was designed to evaluate the relative contribution of the different contractile P2 receptors in endothelium-denuded human coronary arteries by use of extracellular nucleotides, including the stable pyrimidines uridine 5′-O-3-thiotriphosphate (UTPγS) and uridine 5′-O-thiodiphosphate (UDPβS). The isometric tension of isolated vessel segments was recorded in vitro, and P2 receptor mRNA expression was examined by reverse transcription-polymerase chain reaction. αβ-Methylene-adenosine triphosphate (αβ-MeATP) elicited contractions at a low concentration (pEC50 = 5.2), indicating the presence of contractile P2X receptors. The P2Y responses were analyzed after P2X receptor desensitization with 10 μM αβ-MeATP. The stable nucleotides UTPγS and adenosine 5′-O-3-thiotriphosphate (ATPγS), which are agonists of P2Y2 or P2Y4 receptors, were approximately 2 log units more potent than the endogenous UTP and ATP (pEC50 = 4.6 and 3.8 for UTPγS and ATPγS). The efficacy of these responses were approximately double that of the P2X agonist αβ-MeATP (Emax = 125% for UTPγS, 126% for ATPγS, and 68% for αβ-MeATP), suggesting a primary role for contractile P2Y2/4 receptors. The P2Y2 receptor agonist diadenosine tetraphosphate also stimulated contraction, whereas the selective P2Y1 agonist adenosine 5′-O-thiodiphosphate and the selective P2Y6 agonist UDPβS had no effect. Reverse transcription-polymerase chain reaction analysis of mRNA from endothelium-denuded human coronary arteries demonstrated strong bands for P2Y2 and P2X1, although bands for P2Y1, P2Y4, and P2Y6 receptor mRNA could also be detected. In conclusion, the stable pyrimidines UDPβS and UTPγS are important tools for P2 receptor subtype characterization in intact tissues with ectonucleotidase activity. Extracellular nucleotides elicit contraction of human coronary arteries primarily by activation of P2Y2 and P2X receptors, whereas a role for P2Y1 and P2Y6 receptors can be excluded. Antagonists of P2Y2 and P2X receptors may be useful in the treatment of coronary vasospastic disorders.

Footnotes

  • Send reprint requests to: Dr. Malin Malmsjö, Division of Vascular Research, Wallenberg Neuroscience Centre, Lund University Hospital, SE-221 85 Lund, Sweden. E-mail:malin.malmsjo{at}med.lu.se

  • ↵1 This work was supported by the Swedish Heart and Lung Foundation, the Swedish Hypertension Society, the Royal Physiographic Society (Lund), the Jeanson Foundation, the Tore Nilsson Foundation, the Svensson Siblings Foundation, and Swedish Medical Research Council Grants 13130 (to D.E.) and 5958 (to L.E.).

  • Abbreviations:
    αβ-MeATP
    αβ-methylene-adenosine triphosphate
    ADPβS
    adenosine 5′-O-thiodiphosphate
    Ap4A
    diadenosine tetraphosphate
    ATPγS
    adenosine 5′-O-3-thiotriphosphate
    UDPβS
    uridine 5′-O-thiodiphosphate
    UTPγS
    uridine 5′-O-3-thiotriphosphate
    RT-PCR
    reverse transcription-polymerase chain reaction
    bp
    base pair(s)
    • Received November 29, 1999.
    • Accepted February 23, 2000.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 293 (3)
Journal of Pharmacology and Experimental Therapeutics
Vol. 293, Issue 3
1 Jun 2000
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Characterization of Contractile P2 Receptors in Human Coronary Arteries by Use of the Stable Pyrimidines Uridine 5′-O-Thiodiphosphate and Uridine 5′-O-3-Thiotriphosphate
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleCARDIOVASCULAR

Characterization of Contractile P2 Receptors in Human Coronary Arteries by Use of the Stable Pyrimidines Uridine 5′-O-Thiodiphosphate and Uridine 5′-O-3-Thiotriphosphate

Malin Malmsjö, Mingyan Hou, T. Kendall Harden, William Pendergast, Emil Pantev, Lars Edvinsson and David Erlinge
Journal of Pharmacology and Experimental Therapeutics June 1, 2000, 293 (3) 755-760;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleCARDIOVASCULAR

Characterization of Contractile P2 Receptors in Human Coronary Arteries by Use of the Stable Pyrimidines Uridine 5′-O-Thiodiphosphate and Uridine 5′-O-3-Thiotriphosphate

Malin Malmsjö, Mingyan Hou, T. Kendall Harden, William Pendergast, Emil Pantev, Lars Edvinsson and David Erlinge
Journal of Pharmacology and Experimental Therapeutics June 1, 2000, 293 (3) 755-760;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • 4-Chloro ring-substituted synthetic cathinones
  • 14-3-3 Influences Nav1.5 Response to Anti-Arrhythmic Drugs
  • Inhaled Treprostinil Palmitil in the Sugen/Hypoxia Rat Model
Show more Cardiovascular

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics